DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
基本信息
- 批准号:2703454
- 负责人:
- 金额:$ 28.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-07-15 至 2003-04-30
- 项目状态:已结题
- 来源:
- 关键词:MCF7 cell antisense nucleic acid breast neoplasms cathepsin D cell growth regulation estrogen receptors gene expression gene induction /repression genetic transcription growth inhibitors hormone regulation /control mechanism immunocytochemistry immunoprecipitation mutant neoplasm /cancer genetics protein localization protein structure function protooncogene receptor binding receptor expression transcription factor transforming growth factors yeast two hybrid system
项目摘要
DESCRIPTION: The P.I. is investigating a novel method for the
functional inactivation of estrogen receptors (ERs) in estrogen-
dependent human breast cancer cells based on the use of potent dominant
negative (DN) ER mutants. The P.I. has generated several potent DN-ERs
and shown that they inhibit estrogen-stimulated gene expression and
proliferation of breast cancer cells. The present proposal focuses on
two critical advances made during this work: 1 the identification by
2-hybrid interaction cloning of a novel corepressor protein, denoted REA
for repressor of estrogen action. REA selectively enhance the potency
of DN-ERs, while having very little effect on wild type ER and no effect
on other nuclear receptors. 2) The development of a system for
generating targeted DN-ERs which bind with high affinity and selectivity
to specific hormone response elements.
The Specific Aims are: 1) To analyze the molecular mechanisms by which
the corepressor REA is recruited by DN-ERs and potentiates their
activity. Physica and functional mapping of DN-ER/REA interaction will
be carried out using GST pull-down methods, mammalian 2-hybrid
transactivation assays and mutational analyses. Using antibodies to
REA, and antisense methodology, intracellular RE will be
neutralized/eliminated and the functional importance of the DN-ER/REA
interaction will be defined in intact cells. The P.I. will identify
additional REA interaction partners which may potentiate corepressor
activity, and characterize the effect of REA on ER cellular
distribution. 2) To search for other dominant negative corepressors,
the P.I. will use 2-hybrid interaction cloning with the two most potent
DN-ERs. 3) To optimize receptor-corepressor interaction, 2-hybrid
screening with REA will be used to screen ER mutant libraries for
mutants exhibiting enhanced corepressor binding. 4) To assess the roles
of the c-myc, TGFa and cathepsin D genes in the proliferation and
invasiveness of ER positive breast cancer cells, the modified P22
challenge phage system will be used to create DN-ERs that bind
selectively and with high affinity to the different non-consensus EREs
found in each of these genes. The P.I. will introduce the gene-
selective DN-ERs into cells using her efficient adenovirus system,
determine their effects on gene expression, and examine their importance
in ER regulated breast cancer cell proliferation and invasiveness.
别名:The PI正在研究一种新的方法
雌激素受体(ER)的功能失活,
依赖性人乳腺癌细胞的基础上使用有效的显性
阴性(DN)ER突变体。私家侦探已经产生了几种有效的DN-ER
并显示它们抑制雌激素刺激的基因表达,
乳腺癌细胞的增殖。 本建议的重点是
在这项工作中取得了两个重要进展:1.
2-一种新的辅阻遏蛋白REA的杂交相互作用克隆
雌激素作用的抑制物。 REA选择性增强效力
的DN-ER,而对野生型ER的影响非常小,
其他核受体。 2)开发一个系统来
产生以高亲和力和选择性结合的靶向DN-ER
特定的激素反应元素。
具体目的是:1)分析其分子机制,
辅阻遏物REA被DN-ER募集,并增强其
活动DN-ER/REA相互作用的物理和功能映射将
使用GST下拉方法进行,哺乳动物2-杂交
反式激活测定和突变分析。 使用抗体
REA和反义方法,细胞内RE将是
中和/消除和DN-ER/REA的功能重要性
相互作用将在完整细胞中定义。私家侦探将确定
可能增强辅阻遏物的其他REA相互作用伴侣
活性,并表征REA对ER细胞的作用
分布 2)为了寻找其他显性负辅阻遏物,
私家侦探将使用双杂交相互作用克隆两个最有效的
DN-ER。 3)为了优化受体-辅阻遏物相互作用,2-杂交
用REA筛选将用于筛选ER突变体文库,
表现出增强的辅阻遏物结合的突变体。 4)为了评估角色,
c-myc、TGF α和组织蛋白酶D基因在增殖中的作用,
ER阳性乳腺癌细胞的侵袭性,修饰的P22
攻击噬菌体系统将用于产生结合
对不同的非共有ERE具有高亲和力
在每一个基因中。 私家侦探会将基因导入-
使用她的高效腺病毒系统将选择性DN-ER导入细胞,
确定它们对基因表达的影响,并检查它们的重要性,
ER调节乳腺癌细胞增殖和侵袭。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BENITA S KATZENELLENBOGEN其他文献
BENITA S KATZENELLENBOGEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BENITA S KATZENELLENBOGEN', 18)}}的其他基金
Chemical, structural and molecular rules for fully antagonizing the estrogen receptor
完全拮抗雌激素受体的化学、结构和分子规则
- 批准号:
10595881 - 财政年份:2018
- 资助金额:
$ 28.43万 - 项目类别:
Chemical, structural and molecular rules for fully antagonizing the estrogen receptor
完全拮抗雌激素受体的化学、结构和分子规则
- 批准号:
10448445 - 财政年份:2018
- 资助金额:
$ 28.43万 - 项目类别:
Chemical, structural and molecular rules for fully antagonizing the estrogen receptor
完全拮抗雌激素受体的化学、结构和分子规则
- 批准号:
10199959 - 财政年份:2018
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
6376010 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
2895041 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
3204030 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
6512967 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
2101277 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
6172306 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
DOMINANT NEGATIVE ESTROGEN RECEPTORS AND BREAST CANCER
显性负雌激素受体与乳腺癌
- 批准号:
2414275 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
相似海外基金
Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
- 批准号:
22K09003 - 财政年份:2022
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
- 批准号:
21K07762 - 财政年份:2021
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
- 批准号:
20K16927 - 财政年份:2020
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
- 批准号:
20H00526 - 财政年份:2020
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
- 批准号:
20K21245 - 财政年份:2020
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
- 批准号:
G0900887/1 - 财政年份:2011
- 资助金额:
$ 28.43万 - 项目类别:
Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
- 批准号:
05558090 - 财政年份:1993
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
- 批准号:
04453031 - 财政年份:1992
- 资助金额:
$ 28.43万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)